Significant Breakthrough for Stoma Patients

Oslo, Norway (ots/PRNewswire) -

Aimed to dramatically improve the patients' quality of life, The
TIES® System, a new concept of continent ileostomy receives CE-mark.
The CE-mark allows the company to launch the product in the EU/EEU
area.

(Photo: http://photos.prnewswire.com/prnh/20160621/381856 )

Today OstomyCure AS, a Norwegian medical technology company,
announced that TIES® received its CE-mark and will be available in
selected markets. The new solution is a one of a kind revolution for
continent ileostomy, suitable for patients with a permanent
ileostomy.

The TIES® System consists of a small titanium tube implanted into
the abdomen where the intestine and soft tissue grow into it: it is
then sealed with a lid that the patient can open to drain waste
whenever necessary. The lid functions as a stopper.

In conventional stoma surgery, the intestine is extended a few
centimeters outside the abdominal wall, ending in a stoma bag that
adheres to the stomach. Many stoma patients experience difficult
situations at times where the stoma controls their lives. The bag
often creates social limitations for the patients with discomforts
such as skin irritations, infections, allergies and negative stress
due to several toilet visits each day. Other well-known complications
of the conventional ileostomies are parastomal hernias, leakages,
smell and unwanted noise.

"The current USD 2B stoma bag market has only experienced minor
improvements during the last 30 years. TIES® will be a paradigm shift
for the stoma bag users and improve the lives of thousands of
patients" says Dr. Ben Broennimann, M.D. and CEO of OstomyCure.

"The CE-mark is a major milestone and achievement for OstomyCure
and for the patients who will benefit greatly from this significant
technological breakthrough that will increase their quality of life
and give them a new sense of freedom. Without the dedicated,
tenacious hard work of our employees and our research partners with
the vision and patience of our owners we would not have come this
far."

In addition to the groundbreaking benefits for the patients, TIES®
will also provide excellent health economic savings for the local
health authorities. "Our preliminary health economic calculations
have shown that TIES® over a period of a few years will be a less
expensive solution" says Dr. Broennimann, and concludes, "It is our
mission to provide better healthcare and better quality of life for
the stoma users as well as cost benefits for the health authorities
and health care payers."

The TIES® System will initially be launched in a selected number
of countries in Europe.

About OstomyCure:

OstomyCure AS is a medical technology company with its main office
in Oslo, Norway. The company develops a revolutionary technology
called Transcutaneous Implant Evacuation System, The TIES® System for
permanent ileostomies.

The TIES® System is the result of several years of research
combined with the latest 3D manufacturing technology, developed and
produced in accordance with regulatory standards to ensure safety for
the patients.

The company is since August 2011 certified against ISO 13485
Quality Management System for Medical Devices.

The TIES® System received the CE marking in June 2016.

The market that OstomyCure potentially could address is estimated
to be USD 2 billion per year.

http://www.ostomycure.com

Contact information:

Dr. Ben Broennimann, M.D.

CEO, OstomyCure
AS

Phone: +41-79-301-6272

Email: ben@ostomycure.com

Nishant Fafalia

Chairman, OstomyCure AS

Phone +47-902-92765

Email: nishant.fafalia@kistefos.no

OstomyCure AS

Main office:

Oslo Science Park,
Gaustadalléen 21

0349 OSLO, Norway

Stockholm office:

Growhouse, Isafjordsgatan 39B

16440 KISTA,
Sweden

ots Originaltext: OstomyCure AS
Im Internet recherchierbar: http://www.presseportal.de